H1
H2
H3
H4
H5
H6
Text Size h1
Text Size h2
Text Size h3
Text Size h4
Text Size h5
Text Size h6
Body text placeholder. ---- Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis ut sodales ipsum. Fusce tempor laoreet elit ut mattis. Suspendisse ac lacinia nulla. In maximus ex at pretium volutpat. Quisque imperdiet vel nisl semper eleifend. In maximus ex at pretium volutpat. Quisque imperdiet vel nisl semper eleifend.
Paragraph - Body. ---- Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis ut sodales ipsum. Fusce tempor laoreet elit ut mattis. Suspendisse ac lacinia nulla. In maximus ex at pretium volutpat. Quisque imperdiet vel nisl semper eleifend. In maximus ex at pretium volutpat. Quisque imperdiet vel nisl semper eleifend.
Content with image on right
Our Investment Proposition
At Scibase we are on a mission to improving patient's lives through developing accurate detection of skin conditions. We are experiencing rapid growth in our core European market, particularly Germany. Our EU product usage increased in 2022 where we welcomed over 50% new customers. We proudly hold MDR certification in Europe which decreases the barrier to entry for competitors. Our product Nevisense is the only point of care device available for melanoma detection in the US and our presence in the US market holds immense growth potential.
Content with image on left
Our Investment Proposition Left
At Scibase we are on a mission to improving patient's lives through developing accurate detection of skin conditions. We are experiencing rapid growth in our core European market, particularly Germany. Our EU product usage increased in 2022 where we welcomed over 50% new customers. We proudly hold MDR certification in Europe which decreases the barrier to entry for competitors. Our product Nevisense is the only point of care device available for melanoma detection in the US and our presence in the US market holds immense growth potential.
Signpost cards 2
Market Overview
Board of Directors
Simple Table
| Title | Item | Item | Item | Item |
|---|---|---|---|---|
| 2 Mar 2022 | Item | Item | Item | Item |
| 2 Mar 2022 | Item | Item | Item | Item |
| 2 Mar 2022 | Item | Item | Item | Item |
| 2 Mar 2022 | Item | Item | Item | Item |
Accordion
Product portfolio
Nevisense is a non-invasivemedical device designed to assist healthcare professionals in the early detection and assessment of skin conditions, with a primary focus on melanoma, a potentially life-threatening form of skin cancer.
The Nevisense device utilizes a technology called electrical impedance spectroscopy to examine and analyze the electrical properties of skin lesions. By assessing these properties, Nevisense provides real-time data that can aid healthcare professionals in distinguishing between benign and potentially malignant skin lesions.
This technology enables healthcare providers to make more informed decisions regarding the need for further evaluation, biopsies, or treatments.
Nevisense Go Platform Nevisense Go PlatformNevisense Go PlatformNevisense Go PlatformNevisense Go PlatformNevisense Go PlatformNevisense Go PlatformNevisense Go PlatformNevisense Go PlatformNevisense Go Platform Nevisense is a non-invasivemedical device designed to assist healthcare professionals in the early detection and assessment of skin conditions, with a primary focus on melanoma, a potentially life-threatening form of skin cancer.
The Nevisense device utilizes a technology called electrical impedance spectroscopy to examine and analyze the electrical properties of skin lesions. By assessing these properties, Nevisense provides real-time data that can aid healthcare professionals in distinguishing between benign and potentially malignant skin lesions.
Key figures
Content
Commitment to improving patients' lives
Our commitment extends beyond technology. We understand the importance of collaboration between patients, physicians, and technology in the pursuit of healthier skin. By partnering with healthcare providers and institutions, we are working towards a world where skin diseases are detected early, treated effectively, and lives are improved.
Global Reach, Local impact
Headquartered in Sweden, SciBase operates on a global scale. We are dedicated to making our innovative solutions accessible to medical practitioners and patients worldwide.
Our Focus areas on clinical application within skin barrier segment
- Infant AD prediction - strategic collaboration with J&J consumer health
- Objective AD assessment and management
- In-home AD flare predictions and management
Precision and Accuracy
The Nevisense system utilizes a technology called Electrical Impedance Spectroscopy (EIS) to analyze the electrical properties of the skin. This technology involves the application of a small electrical current to the skin's surface through the proprietary Nevisense electrodes. The key significance of these electrodes lies in their ability to provide valuable insights into the condition of the skin. By analyzing the electrical properties of the skin, including its moisture content and cellular structure, the Nevisense system can detect subtle changes or abnormalities that may not be visible to the naked eye.
Form Element Test Page
Signpost cards 1
Sweden
AR Signpost
Calendar
| DATE | TITLE | Calendar Alert | |
|---|---|---|---|
| 18 May 2021 | Annual General Meeting 2021 | Annual General Meeting 2021
Annual General Meeting 2021
|
|
| 16 Jun 2021 | Extra Bolagsstämma 2021-06-16 | Extra Bolagsstämma 2021-06-16
Extra Bolagsstämma 2021-06-16
|
|
| 16 Jun 2021 | Extraordinary general meeting June 16, 2021 | Extraordinary general meeting June 16, 2021
Extraordinary general meeting June 16, 2021
|
|
| 10 Nov 2023 | Interim report Q3 2023 | Interim report Q3 2023
Interim report Q3 2023
|
|
| 19 Aug 2021 | Interim Report Q2 2021 | Interim Report Q2 2021
Interim Report Q2 2021
|
|
| 07 Sep 2021 | Extra bolagsstämma 2021-09-07 | Extra bolagsstämma 2021-09-07
Extra bolagsstämma 2021-09-07
|
|
| 07 Sep 2021 | Extraordinary general meeting September 7, 2021 | Extraordinary general meeting September 7, 2021
Extraordinary general meeting September 7, 2021
|
|
| 11 Nov 2021 | Delårsrapport januari - september 2021 | Delårsrapport januari - september 2021
Delårsrapport januari - september 2021
|
|
| 11 Nov 2021 | Interim Report Q3 2021 | Interim Report Q3 2021
Interim Report Q3 2021
|
|
| 23 Feb 2022 | Bokslutskommuniké 2021 | Bokslutskommuniké 2021
Bokslutskommuniké 2021
|